Immuno-Oncology

The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature

Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013

The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions

Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing strategies for the treatment of melanoma.

Although breakthrough successes are generating a renaissance for anticancer immunotherapies, the framework for translating promising research results into clinical practice remains very much under construction.

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

Bavituximab, Peregrine Pharmaceuticals' lead clinical immunotherapeutic candidate, received Fast Track designation from the FDA to kick off 2014.

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Inhibitory receptors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) expressed on tumor-specific T cells lead to compromised activation and suppressed effector functions such as proliferation, cytokine secretion, and tumor cell lysis.

A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castrationresistant prostate cancer.

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.